- Industry Left Col
- Industry Right Col
HCL Launches a Precompetitive Next Generation Research Platform to Facilitate Collaboration and Accelerate Drug Discovery
PUBLISHED DATE: Jun 20, 2017
Noida, India and Sunnyvale, CA – June 20, 2017 – HCL Technologies (HCL), a leading global IT services company, today announced its Next Generation Research Platform (NGRP), a pre-competitive drug-discovery ecosystem built with open standards. This Platform will provide research scientists with a collaborative ecosystem, greater computational resources, and the ability to mine research data to make more informed scientific decisions, while improving productivity by automating and eliminating manual administrative tasks.
The NGRP is designed to alleviate the technological, economic, and administrative costs that legacy systems and aging technologies pose to pharmaceutical companies. By some estimates, large pharma companies are spending a significant amount of their IT budgets on maintaining these systems. By helping to reduce the expenses associated with legacy systems, the NGRP will free up time and budgetary resources for implementing new capabilities. The NGRP also leverages a design thinking process and journey mapping to simplify a day in the life of a scientist. The Platform allows increased collaboration, the leveraging of innovative technology, improved access to research data, and an increase in the scientist’s productivity.
“HCL is in a unique position to realize the vision to create a precompetitive platform for research IT. We serve seven of the 10 largest pharma companies today and have first-hand knowledge of the challenges in these research IT environments,” said Abhishek Shankar, Vice President – Life Sciences, HCL Technologies. “HCL’s cloud-based NGRP is tailored to alleviate research pain points and enable additional focus on industry’s science-driven core capability of drug discovery.”
For the NGRP, HCL has included managed services in a software-as-a-service model that eliminates the need to manage hardware or maintain and upgrade software for every technology refresh cycle. HCL will also leverage its proprietary DRYiCETM Platform and invest in the high automation of shared operational services, including Dev Ops, regression testing for change and release to reduce cost of services. The best of breed platform approach also helps rationalize research technology portfolio and further reduce costs.
HCL introduced NGRP for broader market consumption in Boston at the 2017 BIO-IT World conference.
About HCL Technologies
HCL Technologies (HCL) is a leading global IT services company that helps global enterprises re–imagine and transform their businesses through Digital technology transformation. HCL operates out of 32 countries and has consolidated revenues of US$ 7.0 billion, for 12 Months ended 31st March, 2017. HCL focuses on providing an integrated portfolio of services underlined by its Mode 1–2–3 growth strategy. Mode 1 encompasses the core services in the areas of Applications, Infrastructure, BPO and Engineering & R&D services, leveraging DRYiCETM Autonomics to transform clients' business and IT landscape, making them 'lean' and 'agile'. Mode 2 focuses on experience–centric and outcome–oriented integrated offerings of Digital & Analytics, IoT WoRKS™, Cloud Native Services and Cybersecurity & GRC services to drive business outcomes and enable enterprise digitalization. Mode 3 strategy is ecosystem–driven, creating innovative IP–partnerships to build products and platforms business.
HCL leverages its global network of integrated co-innovation labs and global delivery capabilities to provide holistic multi–service delivery in key industry verticals including Financial Services, Manufacturing, Telecommunications, Media, Publishing, Entertainment, Retail & CPG, Life Sciences & Healthcare, Oil & Gas, Energy & Utilities, Travel, Transportation & Logistics and Government. With 115,973 professionals from diverse nationalities, HCL focuses on creating real value for customers by taking 'Relationships Beyond the Contract'. For more information, please visit www.hcltech.com
Certain statements in this release are forward-looking statements, which involve a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those in such forward-looking statements. All statements, other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to the statements containing the words 'planned', 'expects', 'believes’,’ strategy', 'opportunity', 'anticipates', 'hopes' or other similar words. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding impact of pending regulatory proceedings, fluctuations in earnings, our ability to manage growth, intense competition in IT services, business process outsourcing and consulting services including those factors which may affect our cost advantage, wage increases in India, customer acceptances of our services, products and fee structures, our ability to attract and retain highly skilled professionals, our ability to integrate acquired assets in a cost-effective and timely manner, time and cost overruns on fixed-price, fixed-timeframe contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, the success of our brand development efforts, liability for damages on our service contracts, the success of the companies /entities in which we have made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property, other risks, uncertainties and general economic conditions affecting our industry. There can be no assurance that the forward-looking statements made herein will prove to be accurate, and issuance of such forward-looking statements should not be regarded as a representation by the Company, or any other person, that the objective and plans of the Company will be achieved. All forward-looking statements made herein are based on information presently available to the Management of the Company and the Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.
For details contact